Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.29 -0.21 (-1.23%)

Delayed Quote Updated: 11:22 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

36 37 Next >

24 Analysts Have This to Say About Sarepta Therapeutics ↗

June 06, 2023

Via Benzinga

NASDAQ:SRPT Shareholder Notice: Investigation over Possible Wrongdoing at Sarepta Therapeutics, Inc. ↗

June 02, 2023

San Diego, CA -- (SBWIRE) -- 06/02/2023 -- An investigation was announced concerning possible breaches of fiduciary duties by certain directors at Sarepta Therapeutics, Inc.

Via SBWire

How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗

June 01, 2023

Shares surged into and out of the company's R&D Day, which included a surprise.

Via Investor's Business Daily

Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval? ↗

June 01, 2023

The stock has now given back all of its 2023 gains as investors' fears mount.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Shares of Sarepta Therapeutics Are Dropping Wednesday ↗

May 24, 2023

The FDA told the company that a review of a new therapy will take nearly a month longer.

Via The Motley Fool

Sarepta Therapeutics Inc. (NASDAQ: SRPT) Leading the Way in Monday Trading Based on Percentage Gain

May 15, 2023

Via Investor Brand Network

Why Sarepta Therapeutics Stock Is Skyrocketing Today ↗

May 15, 2023

Investors are cheering a key FDA advisory committee vote.

Via The Motley Fool

Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 24, 2023

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.

Via Benzinga

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

May 24, 2023

Companies that don't make a lot of noise can still make you a lot of money.

Via The Motley Fool

Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy ↗

May 24, 2023

The company is working to treat Duchenne muscular dystrophy, a muscle-wasting disease.

Via Investor's Business Daily

Why Sarepta Therapeutics Stock Faded This Week ↗

May 11, 2023

The biotech's shares have turned volatile ahead of an important regulatory event.

Via The Motley Fool

Sarepta: The AdCom Documents Enter The Discussion ↗

May 10, 2023

The AdCom documents are going to stimulate a robust discussion about the upcoming vote.

Via Talk Markets

Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001

May 24, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

May 18, 2023

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

Via MarketBeat

Why These 3 Nasdaq Stocks Buckled Today ↗

May 16, 2023

The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.

Via The Motley Fool

Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy

May 16, 2023

Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.

Via MarketBeat

Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

May 15, 2023

Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 15, 2023

Via Benzinga

Why Is Sarepta (SRPT) Stock Up 29% Today? ↗

May 15, 2023

Sarepta (SRPT) stock is on the move Monday as investors react to FDA advisors voting on its gene therapy for Duchenne muscular dystrophy.

Via InvestorPlace

Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024 ↗

May 15, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped nearly 24% on Monday morning after a panel of experts voted last Friday in favor of the company's DMD gene therapy for accelerated approval in...

Via Benzinga

US Stocks Mixed; NY Manufacturing Activity Shrinks In May ↗

May 15, 2023

U.S. stocks traded mixed this morning, with the Dow Jones dropping around 75 points on Monday. Following the market opening Monday, the Dow traded down 0.23% to 33,224.02 while the NASDAQ rose 0.18% to...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 15, 2023

Via Benzinga

Benzinga Pro's Top 5 Stocks To Watch For Monday, May 15, 2023: TSLA, SRPT, TJX, MNDY, LTRY ↗

May 15, 2023

Tesla (TSLA) - The company will host its annual shareholder meeting on Tuesday. The event will be broadcast on YouTube and begins at 4 p.m. EDT. A reminder that annual shareholder meetings are

Via Benzinga

Why Sarepta Therapeutics Stock Is Soaring Today ↗

May 15, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher Monday after the company announced the FDA voted in favor of its gene therapy to treat Duchenne muscular dystrophy late...

Via Benzinga

FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder ↗

May 15, 2023

On Friday, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene...

Via Benzinga

2 Supercharged Growth Stocks to Buy Right Now ↗

May 14, 2023

These two biopharma stocks might be poised for a major breakout.

Via The Motley Fool

Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

May 12, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy ↗

May 12, 2023

The gene therapy would treat Duchenne muscular dystrophy, a muscle-wasting disease.

Via Investor's Business Daily

FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote ↗

May 10, 2023

The FDA's Cellular, Tissue and Gene Therapies Advisory Committee is meeting this Friday to discuss Sarepta Therapeutics Inc's (NASDAQ: SRPT) to review SRP-9001 (delandistrogene moxeparvovec),...

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.